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Although the role of p53 as a tumour suppressor in renal cell carcinoma (RCC) is unclear, our recent analysis suggests that increased wild-type p53 protein expression is associated with poor outcome. A growing body of evidence also suggests that p53 expression and increased co-expression of MDM2 are linked with poor prognosis in RCC. We have therefore examined whether an MDM2 antagonist; Nutlin-3, might rescue/increase p53 expression and induce growth inhibition or apoptosis in RCC cells that retain wild-type p53. We show that inhibition of p53 suppression by MDM2 in RCC cells promotes growth arrest and p53-dependent senescence - phenotypes known to mediate p53 tumour suppression in vivo. We propose that future investigations of therapeutic strategies for RCC should incorporate MDM2 antagonism as part of strategies aimed at rescuing/augmenting p53 tumour suppressor function.





The incidence of cancer of the kidney is increasing in the developed world. For example the age-adjusted incidence has risen from 5 to approximately 11/100,000 in the last 30 years in the UK []. Despite advances in understanding of the molecular biology of RCC and related drug developments, targeting consequences of VHL mutations (increased VEGF) or mTOR dependence, patients with metastatic disease have an extremely short life expectancy []. Accordingly, identifying other pathways that define novel therapeutic targets remains a high priority. In the present study we have focused on the role of the p53 pathway in renal cancers (reviewed in []). Although the literature on p53 in RCC contains seemingly conflicting data [], a recent review of the evidence suggests that a re-interpretation of the existing information on the status of the p53/MDM2 pathway provides a way to resolve this discrepancy []. Specifically, whilst mutations in the p53 gene (TP53) were not predictive of outcome, up-regulation of p53 expression was and moreover, p53 expression is strongly linked with expression of MDM2  ADDIN EN.CITE [, ], a conclusion further supported by our own recent study []. In a cohort of 90 renal cell carcinoma patients, we found that p53 expression was linked with MDM2 (P=0.000013) and that co-expression was linked with reduced disease specific survival in both univariate (P=0.036) and Cox multivariate (P=0.027) analyses []  and []. These results are similar to those obtained in the only two other studies to have previously examined p53 and MDM2 expression in RCC, demonstrating associated co-expression  ADDIN EN.CITE [, ] and in the one case where outcomes were analysed, co-expression was also linked with poorer outcome []. It seemed likely that the mechanism linking p53 and MDM2 expression was due to p53-dependent transcription of MDM2 in these cells []. Of course, this explanation demands that the p53 up-regulated in these cells is wild-type, and not surprisingly, our study found that indeed, in 86% of cases, up-regulated p53 was wild-type, thus providing support for this explanation for co-expression [].

This then begs the question of how up-regulation of wild-type p53 can be linked with poor prognosis in cancer. The most probable explanation may be that the associated MDM2 expression can promote phenotypes associated with more aggressive disease. For example, MDM2 can promote increased cell motility and invasiveness [] and thus it may be that the contribution of wild-type p53 is indirect and is mediated via increased MDM2 expression. 

Critically, the observed association between retention of up-regulated wild-type p53 in RCC patients and co-expression of MDM2, also provides support for in vitro data from previous studies by ourselves and others showing that p53 in RCC cells is at least partially functional  ADDIN EN.CITE [, , ]. 

If wild-type p53 is retained in RCCs and promotes co-expression of MDM2 as a consequence of wild-type p53-mediated transcription of the MDM2 gene, then this suggests that although p53 is partially transcriptionally active in these cells, it critically fails to promote tumour-suppressive activities in RCC. We have therefore investigated whether we could rescue p53 in RCC cells by targeting its negative regulator MDM2, to promote phenotypes that contribute to tumour suppression: apoptosis and/or senescence. A key question arising from this model (since expression of MDM2 is up-regulated in response to p53 up-regulation, but apparently fails to promote efficient degradation of p53), is whether targeting of MDM2 in these cells will prove an effective strategy to activate a tumour suppressing phenotype in RCC cells. As proof of principle we show here that Nutlin-3, the small molecule inhibitor of MDM2-p53 interaction, effectively induces growth arrest and senescence in RCC cells and that this senescence is p53-dependent. Thus due to the unusual nature of the p53 pathway in RCC there exists a unique opportunity to rescue wild-type p53 function in a sub-set of poor prognosis and biomarker-defined patients (i.e. wild-type p53+ve/MDM2+ve) which clearly warrants further investigation. 

2.	Materials, and Methods 
2.1 Antibodies
Antibodies for β-actin (C-2), p21 (F-5) and BAX (N-20) were obtained from Santa Cruz Biotechnology. Antibodies for, p53 (DO-1) and MDM2 (IF2) were from Calbiochem and anti-BrdU (B44) for flow cytometry was from Becton Dickinson. Anti-mouse and anti-rabbit HRP were from GE Healthcare.

2.2 Plasmids, siRNAs and transfection
pRDI-22 was a kind gift of Richard Iggo. siRNAs (Dharmacon) and their use have been described previously  ADDIN EN.CITE [, , ]. ACHN cells expressing shRNA for either p53 or a scrambled control sequence based on previously described siRNAs [] were generated as follows: oligonucleotide duplexes were cloned into pSUPER-puro vector (Oligoengine) according to the manufacturer’s protocol. ACHN cells were transfected with shRNA vectors using GeneJuice (Novagen) essentially as described previously [], and selected for four days in media supplemented with 1.5g/ml puromycin. Subsequently cells were maintained under selection of 0.75g/ml puromycin. Colonies were identified, picked and expanded before being analysed by western blotting.

2.3 Cell culture and western blot analysis
Cell lines ACHN, A498 and Caki-2 were obtained directly from the ATCC. Cell lines 111, 115, 117 and 154 were generated by Prof. W.M. Linehan and were kindly provided directly to us. In all cases, aliquots of low passage cells were frozen and then as required these were recovered for use in these studies. No cell line was in culture continuously for more than 6 months prior to analysis.  Cells were maintained, treated with Nutlin-3 (Sigma), harvested and processed for western blotting as described previously  ADDIN EN.CITE [, , , ].

2.4 Quantitative RT-PCR analysis of MDM2 mRNA
Q-RT-PCR analysis of transcripts initiated in the P1 and P2 promoters of the human MDM2 gene was performed as we have previously described  ADDIN EN.CITE []. Ct values were converted to relative mRNA transcript abundance using the standard curve method and then normalised to the abundance of GAPDH mRNA in the sample.

2.5 Proliferation and senescence assays
These were performed as described previously  ADDIN EN.CITE []. MTT (Sigma) was added to cells for three hours and absorbance measured using a Thermo-Multiskan plate reader.

2.6 Flow cytometry
Flow cytometry was performed as described previously,  ADDIN EN.CITE [] except for BrdU incorporation which was performed as follows: cell nuclei were extracted as described  ADDIN EN.CITE [], incubated sequentially in anti-BrdU and anti-mouse FITC secondary antibody solutions in PBS with 0.5% Tween-20 and 1% BSA, re-suspended in 1g/ml propidium iodide in PBS and analysed using a BD FACScalibur flow cytometer.    

3.	Results
p53 promotes transcription of the MDM2 gene from the P2 promoter, normally as part of a stress response. We therefore measured the relative levels of P1 and P2 MDM2 transcripts in a panel of RCC cell lines and for comparison also in a wild-type p53 non-RCC cell line (U2Os - osteosarcoma) as Figure 1 shows (note that none of these lines harbour amplifications of the MDM2 gene- as supplementary data Figure 1 illustrates). With one exception; 117 cells which harbour wild-type p53 (confirmed functionally (see panel 1C) and by sequence analysis, not shown) all of the p53 lines can be correctly identified as harbouring wild-type or mutant p53 using an empirically determined threshold value of 0.85. Some studies have suggested that the MDM2 P2 promoter is not exclusively up-regulated by p53  ADDIN EN.CITE [, , ], and in mice, low/basal levels of MDM2 P2 transcripts can be detected in both wild-type and p53-/- animals []. However only in p53 wild-type animals is P2 activated by stress and even in studies that have found evidence of other regulators of P2 transcription, p53 status strongly predicted P2 activity  ADDIN EN.CITE []. These studies form part of an overwhelming body of evidence which clearly demonstrates that p53-dependent activation of P2 is a primary determinant of MDM2 up-regulation in response to stress. Therefore, since only p53 has been demonstrated to induce MDM2 expression from P2 in response to stress, and since stresses that activate this include oncogenic stress, we conclude that the most likely explanation for the association we observe in RCC cells between p53 status and P2 expression, is that the transcription from P2 that we have observed is a consequence of p53 activity.  

To resolve the question of p53 function and P2 transcription in the 117 cell line, the only exception to the expected pattern in our study, we have analysed two additional clonal derivative lines which stably express either a dominant negative mutant of p53 (R175H) or wild-type p53 (described previously []). Whilst the level of P2 transcript in these cells expressing exogenous wild-type p53 from an integrated plasmid does not reach the threshold level determined for other cell lines, though it does increase significantly. Thus it appears that in this cell line p53 activity is in some way suppressed for reasons that are unclear. We therefore examined the p53-depedance of MDM2 expression in these cells by RNAi and found that p53 activity does regulate MDM2 levels in 117 cells as Figure 1C shows (in accordance with our previously published studies  ADDIN EN.CITE [, ]). Thus in 9/9 p53 wild-type RCC cell lines analysed (and in 0/5 p53 mutant RCC lines) p53 activity promotes expression of MDM2. This strongly suggests that the association identified previously  ADDIN EN.CITE [, ] which we have subsequently confirmed in patient samples [] between p53 expression and MDM2 expression in RCC is likely the result of p53-mediated promotion of MDM2 expression from the P2 promoter of MDM2 []. 

In p53 wild-type RCC lines we have always seen that RNAi-mediated reduction in MDM2 leads to an increase in p53 expression levels  ADDIN EN.CITE [, ] an observation confirmed by others  ADDIN EN.CITE [, ]). Thus the question arises whether targeting MDM2 in RCC cells might rescue p53 from the negative regulatory effects of MDM2 and what the consequences of this would be.
 
We therefore used Nutlin-3, a small molecule inhibitor of p53-MDM2 interaction (which competitively binds to the p53 binding site on MDM2)  ADDIN EN.CITE [, ] to examine this question. Figure 2 demonstrates that Nutlin-3 inhibits proliferation in all (5/5) of the p53 wild-type RCC cell lines tested in a dose-dependent manner. We have found that all of these RCC lines express MDMX (MDM4, not shown), another critical negative regulator of p53, and therefore the efficacy of Nutlin-3 suggests that there is insufficient MDMX to inhibit p53 when MDM2-p53 interaction is inhibited by Nutlin-3 in these lines. We note that there is no effect of Nutlin-3, even at relatively high concentrations on the p53 mutant lines. It is also noteworthy that 117 cells, which express the lowest levels of MDM2 P2 mRNA appear to be more resistant to the effects of Nutlin-3.  Figure 3 shows that treatment of RCC cells with Nutlin-3 leads to increased expression of p53 and some p53 target genes: MDM2, and p21 (CDKN1A), but not BAX which accords with observations showing that p53 functions to regulate a sub-set of potential target genes in RCC cells []. 





The status of p53 in RCC is an important question, particularly in RCCs in which MDM2 is co-expressed due to the association with reduced survival  ADDIN EN.CITE [, ], since as we show here, it might be possible to rescue the tumour suppressive function of wild-type p53 in such cases. Achieving this however, may be less straightforward than it initially appears as there has been some debate regarding the extent to which p53 functions normally in the kidney  ADDIN EN.CITE [, , , ]. p53 function undoubtedly displays signs of selective impairment in kidney, as illustrated for example by studies of transgenic mice exposed to ionising radiation which display stabilisation of p53 in the kidney in the absence of apoptosis [] (also reviewed in []), as well as by our results which indicate that only some p53 target genes are up-regulated in Nutlin-3 treated cells.

Nevertheless, whilst the observations in transgenic mice suggest that the p53 pathway is compromised, evidence from other systems supports a role for loss of p53 function being a carcinogenic event in the kidney. For example, loss of p53 function through mutation accelerates renal carcinogenesis in a mouse model of cancer []. Thus it seems likely that wild-type p53 up-regulated in some RCCs, promotes MDM2 expression, and this combination promotes disease progression, all in the context of partial loss of p53 tumour suppressor function. Given the importance of p53 as a tumour suppressor and mediator of cellular responses to chemotherapeutic agents in many tissues, we clearly need to determine whether ways can be found to rescue the function of the wild-type p53 present in these RCCs. One possible obstacle to making progress in this may be the relative lack of focus of research into the p53 pathway in RCC.

Of more than 70,000 p53-related papers on PubMed in 2014 only approximately 1% refer to renal cancer and the reason for this relative lack of focus may be partly historical. In many other cancers mutations in p53 are the single most common genetic alteration, indeed across all human cancers loss of p53 function through a variety of direct and indirect mechanisms seems almost ubiquitous (reviewed in []). Furthermore, in most cancers, loss of p53 function has been linked with disease development, progression and/or poor response to therapy (reviewed in []). However in RCC, it has been known for some time  that p53 mutations are relatively rare []. In addition, it has only relatively recently become apparent that up-regulation of wild-type p53 (but not mutation of p53) is associated with outcome in RCC [], as reviewed in []. 

Clearly, it is important to distinguish p53 status as inferred (and most often wrongly so in the case of RCC) from IHC studies, from studies using genotyping with or without analysis of p53 expression levels. Only two previous studies have attempted to determine both p53 expression profiles and genotype in RCC  ADDIN EN.CITE [, ], and whilst neither identified a link with outcome, both found that mutational frequencies were lower than the frequency of increased p53 expression (0% and 10% versus 23% and 33% respectively). Notwithstanding this, a growing body of evidence shows that increased p53 expression is associated with disease progression in RCC (reviewed in []). 

From a biological perspective it is of considerable interest that the up-regulated wild-type p53 in RCC cells selectively promotes expression of, inter alia, MDM2 and p21, without apparently inducing tumour suppression in RCC tumours. How this selectivity arises will be important to determine since this may shed light on pathways amenable to therapeutic manipulation. All we can say at present is that some p53 target genes are induced by inhibiting MDM2 in vitro and that some of these, such as p21 (CDKN1A), do elicit the expected phenotype (cell cycle arrest) under conditions in which p53 activity is further induced []. Whether the absence of apoptosis following p53 induction is a consequence of failure to induce pro-apoptotic genes, or due to failure to respond to these requires further investigation, though the earlier observations of p53 stabilisation in the absence of apoptosis in the kidney of mice exposed to ionising radiation suggest that this is a property of this tissue and not a feature unique to the tumour cells derived from it []. Nevertheless, the ability of this pathway to induce senescence in RCC cells when further activated, suggests that by finding means to accomplish this pharmacologically, we can promote phenotypes that should act to suppress tumours.

As described above several existing lines of evidence from clinical, and experimental studies performed in vivo and in vitro, suggest the existence of kidney-specific aspects to the function/regulation of the p53/MDM2 axis, and hence to renal carcinogenesis involving p53  ADDIN EN.CITE [, , ]. 

To this we now add data which demonstrate that:
i)	in RCC cells, p53 activity promotes MDM2 expression and that MDM2 negatively regulates p53. 
ii)	MDM2 activity is amenable to inhibition by small molecules resulting in rescue of p53 activity leading to growth arrest and senescence in RCC cells. 
iii)	Senescence induced by Nutlin-3 is p53-dependent

Thus our studies not only add support to the conclusion that there are tissue-specific defects in the p53/MDM2 pathway in RCC, but also show that direct inhibition of MDM2-mediated regulation of p53 may provide a means of rescuing some of the dormant tumour suppressor activities of p53 in these cells [] (note that direct inhibition of MDM2 may have different consequences from indirect activation of p53 with chemotherapy/radiation which does not work in RCC - perhaps due to concomitant induction of MDM2 following such genotoxic stress). Indeed, since p53 is such a potent tumour suppressor [], this may provide benefit even in advanced disease for patients that retain wild-type p53 since up-regulation of p53 is associated with advanced disease stage  ADDIN EN.CITE [, ]. 

Data presented in Supplementary data Figure 2 show that there is little if any detectable increase in apoptosis in cells treated with Nutlin-3a. This observation is independent of the p53 status of the cells and of the levels of MDM2 present. Analysis of data shown in Figure 4, in which we have measured BrdU incorporation, indicates that cells that retain wtp53 exhibit a dramatic reduction in S phase, which is likely to be a result of cells exiting the cell cycle. This also accords with the observed increase in cellular senescence shown in Figure 5. Thus one of the features of RCC cells treated with Nutlin-3a is their exit from the cell cycle in the absence of cytotoxicity. Treatment strategies that aim to incorporate Nutlin-like drugs may require combinatorial approaches to increase toxicity, although this will not be trivial since normal proliferating cells are likely to be sensitive to combinations with conventional chemotherapeutic agents. Since many classical chemotherapies target cell proliferation, and Nutlin-3a removes cells from the cell cycle, it seems probable that combinations will need to target other aspects of cancer cells such as their dependence upon aerobic glycolysis  ADDIN EN.CITE [, ] or the consequences of defects in VHL function[] if acceptable therapeutic indices are to be achieved.

MDM2 has been shown to induce increased cell motility and invasiveness in a range of cell types including in RCC cells  ADDIN EN.CITE [, , ]. Since treatment with Nutlin leads to an increase in the MDM2 level in all of the p53-wild-type RCC cell lines we have tested, as illustrated in Figure 3, and since this is likely to be a p53-dependent effect, it is possible that there may be some dangers in using an MDM2 antagonist to treat patients with tumours that harbour wild-type p53, such as increasing metastatic potential. Such issues require careful examination in vitro, in pre-clinical studies and in clinical trials.  

In addition to Nutlin-3 and its derivatives and related compounds such as RG7112, the first to be tested in clinical trials  ADDIN EN.CITE [], a number of other compounds have been developed that act in a similar manner as MDM2 antagonists. These compounds, such as the isoindolinones  ADDIN EN.CITE [] and the MI- series of compounds [] clearly merit careful investigation as agents that might have promise not only in the broad context of wild-type p53 in cancer generally, but in particular in RCC where wild-type p53 is linked with more aggressive disease[].

Not surprisingly, our studies also raise several questions regarding p53/MDM2 function in RCC, for example, how can high levels of p53 and MDM2 co-exist in RCC cells since MDM2 normally promotes ubiquitylation and degradation of p53 []? It is noteworthy that MDM2 appears functional, or at least partially so with respect to regulation of p53 in these cells as shown in Figure 1C and as we have reported previously  ADDIN EN.CITE [, ], indeed our use of Nutlin-3 depends upon this, and thus other mechanisms/pathways must prevent more efficient degradation of p53. Also, how do these cells proliferate and produce tumours when up-regulation of p53 that occurs in the tumour, promotes increased expression of several target genes including p21 (CDKN1A) that normally inhibit cell proliferation and/or induce senescence and indeed can be made to induce these phenotypes in vitro? Future studies of this may identify better ways to enhance the p53 tumour suppressive response in these cells that could be put to therapeutic use.

The use of Nutlin to activate p53 responses in cells from a variety of origins is well documented (for review see  ADDIN EN.CITE []). The novelty of our studies lies in the context together with the demonstration that RCC cells primarily respond to p53 activation by undergoing cell cycle exit and senescence, not apoptosis. This becomes of greater significance in RCC cells because, as we have shown, in patients with RCC, tumours that harbour the highest levels of wild-type p53, are associated with poorer prognosis []. Thus we suggest that RCC may provide a rare opportunity to therapeutically target tumours with a poor prognosis, defined by an unusual biomarker: up-regulated wild-type p53.

In conclusion, our findings that over-expressed p53 in RCC is frequently wild-type and is strongly linked with MDM2 co-expression led us to examine inhibition of MDM2-mediated regulation of p53 as a potential drug target in RCC. As proof-of-principle we used Nutlin-3, an experimental antagonist of the p53-MDM2 interaction, to determine whether activation of endogenous p53 might provide an effective means of inhibiting RCC cell proliferation. As the data show, this approach looks promising in vitro and warrants further investigation in preclinical studies. Nutlin-3 inhibits proliferation and importantly, given its role in p53-mediated tumour suppression [], induces p53-dependent senescence, thus indicating that inhibition of MDM2-mediated regulation of p53 in RCCs harbouring wild-type p53 could become part of future therapeutic strategies.
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Figure 1. p53 is active in RCC cells, promotes MDM2 expression and is subject to negative regulation by MDM2. Panels A and B show the results of quantitative RT-PCR analysis of transcripts initiated in the P1 and P2 promoters of the human MDM2 gene. mRNA abundance is expressed  relative to transcript levels in 786-0 cells, a representative mutant p53 expressing cell line. Mean and standard deviation of duplicate assays performed on the same cDNA are shown. The dotted line indicates an empirically determined cut-off value for P2 levels that correctly identifies the p53 status of 13/14 RCC lines. Black bars show renal cancer cell lines, grey bars are sub-clones of the 117 cell line, and open bars show the wild-type p53-expressing U2OS osteosarcoma line for comparison. P value comparing MDM2-P2 transcripts in wild-type vs mutant p53-expressing renal cancer cell lines was determined by Student’s T-test (2-sided, unpaired). C. Western blot analyses for the indicated proteins from lysates of 117 cells following transfection with the indicated siRNAs. Cells were transfected with siRNAs and harvested 48 hours later. Experiments shown are typical from a single experiment repeated on at least three occasions.

Figure 2. Proliferation of RCC cells harbouring wild-type p53 is inhibited in a dose-dependent manner by Nutlin-3. RCC cells (1,000/well 117 and 115 cells, 2,500/well Caki-2 and A498 cells and 5,000/well ACHN, 111 and 154 cells) were seeded in quadruplicate into 96 well plates and 24 hours later (time 0) were treated with the indicated concentrations of Nutlin-3 or with DMSO (vehicle) control. Media and drug were replenished every second day. Wells were incubated with MTT at the indicated time points and the optical absorbance at 590nm was measured. Error bars represent the s.e.m. from four independent wells. Experiments shown are typical from a single experiment repeated on at least three occasions. 

Figure 3. Nutlin-3 induces changes in steady state levels of expression in p53 and p53 target genes in RCC cells. Western blot analysis of protein lysates from RCC cells. A. Lysates from cells harvested 48 hours after treatment with the indicated concentration of Nutlin-3. B. Lysates from untreated cells to enable comparison of endogenous protein levels. All lanes were loaded with 50μg of protein. Blots were probed with antibodies for p53, MDM2, p21, BAX and β-actin (protein loading control) as indicated. The results shown are from a typical experiment repeated on at least three occasions.

Figure 4. Nutlin-3 induces cell cycle arrest in p53 wild-type RCC cells. Results obtained by flow cytometry of fixed RCC cell nuclei stained with propidium iodide and in insets showing BrdU incorporation. Cells were seeded and treated for 48 hours with either DMSO or Nutlin-3 as indicated. Nutlin-3 was added at the following concentrations: 5μM for ACHN, Caki-2, A498 and 115 and 20μM for 117, 111 and 154 cells, higher doses being used where no effect was apparent at lower doses. 30 minutes before harvesting 20μM BrdU was added to the media and then the cells were harvested and processed as described in materials and methods. The results shown are from a typical experiment repeated on at least three occasions. wt; indicates wild-type and mt; indicates mutant.

Figure 5. Nutlin-3 induces p53-dependent senescence in RCC cells.
Senescence associated (SA) β-galactosidase assay of RCC cells treated with the indicated concentration of Nutlin-3 in DMSO for 48 hours for RCC cell lines in A. and B. and in C. for derivatives of ACHN cells expressing the indicated shRNAs (Note the different scales on the ordinates in each panel). Following treatment, cells were then fixed and incubated with X-Gal at low pH (6.0). Three fields were scored per condition and the percentage of senescent cells as a fraction of the total was calculated. A minimum of 200 cells were scored for each condition. Error is expressed as the s.e.m. Statistical analysis performed by Student’s t-test (two-tailed). The results shown are from a typical experiment repeated on at least three occasions. D. Shows western blot analysis of lysates from the indicated shRNA expressing cell lines analysed in C, probed with antibodies to the indicated proteins. 
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